Importance of Genomic Testing for Patients With Metastatic Prostate Cancer

By Tanya Dorff, MD, Neeraj Agarwal, MD - Last Updated: November 14, 2023

In the fourth part of this peer-to-peer discussion at the 2023 Uromigos Live & Unplugged event, Tanya Dorff, MD, City of Hope, and Neeraj Agarwal, MD, University of Utah, share how crucial it is for metastatic prostate cancer patients around the world to undergo germline or tumor somatic gene testing.

This testing is important, even thought there is not yet a targeted therapy available for these patients in the hormone-sensitive setting, says Dr. Agarwal.

View the other parts of this discussion, including Talazoparib Plus Enzalutamide: TALAPRO-2 Results and Subset Analyses, TALAPRO-2: Toxicities and Treatment Duration, and How Has TALAPRO-2 Changed the Standard of Care for First-Line mCRPC With HRR Mutations.

Post Tags:Uromigos Live 2023-Prostate Cancer